



CLINICAL TRIALS FOR BRAIN TUMOURS

OPEN AT ROYAL NORTH SHORE HOSPITAL & NORTHERN SYDNEY CANCER CENTRE.

1. Low Grade Glioma (WHO Grade II):
 - a. Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study. Intergroup Study (EORTC 22033-26033) (**CLOSED**)
2. High Grade Glioma (WHO Grade III):
 - a. Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non- 1p/19q deleted anaplastic glioma. The CATNON Intergroup trial. Intergroup Study (EORTC 26053_22054)
3. High Grade Glioma (WHO Grade IV):
 - a. Cilengitide for subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter - a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone (CENTRIC). Merck KGaA EMD 121974-011
 - b. A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and radiotherapy followed by placebo and temozolomide in patients with newly diagnosed glioblastoma. F.Hoffmann-LaRoche Ltd. BO21990 / A
 - c. Phase II study of Cilengitide in combination with concurrent chemo- and radiotherapy followed by protracted daily low dose temozolomide (TMZ) and low dose procarbazine D1 – 20 in newly diagnosed glioblastoma without methylation of the MGMT promoter gene (Ex-CENTRIC) Merck KGaA EMD 121974
 - d. A randomized phase III study of temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients. NCIC CTG CE.6
4. Recurrent High Grade Glioma:
 - a. A phase 1b/2 study of CYT997 in combination with carboplatin in relapsed GBM .CCL08001 (**CLOSED**)
5. Brain Metastases:
 - a. Melanoma: Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma– A randomised Phase III trial. ANZMTG/SNOG/TROG/NHMRC CTC
 - b. Non-Small Cell Lung Cancer: A Phase III multi-centre randomized controlled trial to assess whether optimal supportive care alone is as effective as optimal supportive care plus whole brain radiotherapy in the treatment of patients with inoperable brain metastases from non-small cell lung cancer (QUARTZ). MRC LU 24/ TROG 0702.